» Articles » PMID: 11278955

Molecular Cloning of MIS, a Myeloid Inhibitory Siglec, That Binds Protein-tyrosine Phosphatases SHP-1 and SHP-2

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2001 Mar 30
PMID 11278955
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

We describe the molecular cloning and characterization of a novel myeloid inhibitory siglec, MIS, that belongs to the family of sialic acid-binding immunoglobulin-like lectins. A full-length MIS cDNA was obtained from murine bone marrow cells. MIS is predicted to contain an extracellular region comprising three immunoglobulin-like domains (V-set amino-terminal domain followed by two C-set domains), a transmembrane domain and a cytoplasmic tail with two immunoreceptor tyrosine-based inhibitory motif (ITIM)-like sequences. The closest relative of MIS in the siglec family is human siglec 8. Extracellular regions of these two siglecs share 47% identity at the amino acid level. Southern blot analysis suggests the presence of one MIS gene. MIS is expressed in the spleen, liver, heart, kidney, lung and testis tissues. Several isoforms of MIS protein exist due to the alternative splicing. In a human promonocyte cell line, MIS was able to bind Src homology 2-containing protein-tyrosine phosphatases, SHP-1 and SHP-2. This binding was mediated by the membrane-proximal ITIM of MIS. Moreover, MIS exerted an inhibitory effect on FcgammaRI receptor-induced calcium mobilization. These data suggest that MIS can play an inhibitory role through its ITIM sequences.

Citing Articles

Siglec-E augments adipose tissue inflammation by modulating TRAF3 signaling and monocytic myeloid-derived suppressor cells during obesity.

Rakib A, Mandal M, Mamun M, Kiran S, Yasmen N, Li L Front Immunol. 2025; 16:1501307.

PMID: 39967660 PMC: 11832521. DOI: 10.3389/fimmu.2025.1501307.


Sialic Acid-Siglec-E Interactions Regulate the Response of Neonatal Macrophages to Group B Streptococcus.

Lund S, Del Rosario P, Honda A, Caoili K, Hoeksema M, Nizet V Immunohorizons. 2024; 8(5):384-396.

PMID: 38809232 PMC: 11150127. DOI: 10.4049/immunohorizons.2300076.


Dissecting the Ability of Siglecs To Antagonize Fcγ Receptors.

McCord K, Wang C, Anhalt M, Poon W, Gavin A, Wu P ACS Cent Sci. 2024; 10(2):315-330.

PMID: 38435516 PMC: 10906256. DOI: 10.1021/acscentsci.3c00969.


Discovery, classification, evolution and diversity of Siglecs.

Angata T, Varki A Mol Aspects Med. 2022; 90:101117.

PMID: 35989204 PMC: 9905256. DOI: 10.1016/j.mam.2022.101117.


Ablation of Siglec-E augments brain inflammation and ischemic injury.

Li L, Chen Y, Sluter M, Hou R, Hao J, Wu Y J Neuroinflammation. 2022; 19(1):191.

PMID: 35858866 PMC: 9301848. DOI: 10.1186/s12974-022-02556-1.